Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Wall Street Journal - November 9, 2007
John Carreyrou, john.carreyrou@wsj.com
Four big pharmacy chains and one pharmaceutical wholesaler filed a lawsuit against Abbott last month, alleging that it abused its monopoly in the U.S. market for AIDS drugs with the price hike. Abbott is also being sued by two AIDS patients and the Service Employees International Union Health and Welfare Fund. That suit has class-action status and is scheduled to go to trial in June.
In its complaint filed in U.S. District Court in Oakland, Calif., Glaxo alleges that Abbott "schemed to removeà one of the critical components" of AIDS drug cocktails from the U.S. market by raising the price of its drug, Norvir, by 400%. The move, Glaxo alleges, undercut a Glaxo drug, Lexiva, which is used in cocktails in combination with Norvir. Norvir's U.S. wholesale price rose to $257.10 from $51.30 for 30 100-milligram capsules.
Norvir, which received Food and Drug Administration approval in 1996, is in a class of drugs known as protease inhibitors. Side effects prevented it from being used as a stand-alone drug, but it became widely used in small doses to boost the effectiveness of other protease inhibitors. In 2000, Abbott introduced Kaletra, a pill that includes Norvir.
Abbott's decision to quintuple Norvir's price in the U.S. made Kaletra a cheaper option for American AIDS patients, as it raised the cost of regimens pairing Norvir with rivals' drugs by several thousand dollars a year.
"This frivolous lawsuit is completely without merit," Abbott spokeswoman Melissa Brotz said.
In January, The Wall Street Journal reported that Abbott discussed two alternatives to a Norvir price increase. One was to sell Norvir only as a liquid, which one Abbott executive said tasted like vomit. That would have discouraged use of Norvir with competitors' drugs, Abbott executives reasoned. Another was to stop selling Norvir altogether. Abbott says it never seriously considered those scenarios. It also says competitors' drugs have since gained market share.
071109
WJ071102
Copyright © 2007 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .